Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 15 May 2024 AM
The eye market is heating up, with Roche and Bayer scrambling for top spot, but a gene therapy being developed by AbbVie may trump both of them.
Bayer's Eylea has long dominated the eye market, but when Roche's Vabysmo, which requires fewer injections arrived, it was predicted to quickly steal market share.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.